Cronos Group Announces 10.5% Investment Into US Operator PharmaCann

It appears that rules pertaining to ownership of US cannabis operations are loosening at the TSX Exchange and US big boards. Cronos Group (TSX: CRON) this morning announced that it has entered into an arrangement whereby a wholly owned subsidiary has acquired the option to purchase a stake in US operator PharmaCann.

The transaction will see Cronos, via a subsidiary, acquire an option to purchase a 10.5% ownership stake in PharmaCann, a multi-state operator. Much like Canopy Growth’s arrangement with Acreage Holdings, the final exercise of the option is to be dependent upon US federal legalization.

PharmaCann currently has six production facilities and 23 dispensaries within six states. The states, which include New York, Illinois, Maryland, Pennsylvania, Ohio and Massachusetts, are limited license states.

Under the terms of the transaction, Cronos paid $110.4 million to acquire the option in PharmaCann, which is to be paid directly to PharmaCann shareholders. Commercial agreements are expected to be entered into later this year that will see the two parties allowed to offer products through either party’s distribution channels. Cronos is also to be permitted to elect one director of PharmaCann once the option is exercised.

Notably, Michael Gorenstein, whom is executive chairman of Cronos, as well as Jason Adler, a director of Cronos, hold an indirect state in PharmaCann via their interest in Gotham Green Partners, whom is a shareholder of PharmaCann.

Cronos Group last traded at $10.82 on the TSX.


Information for this briefing was found via Sedar and Cronos Group. The author has no securities or affiliations related to these organizations. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

Cronos Group, Ginkgo Bioworks Achieve Partnership Productivity Target For CBG Acid

Cronos Group, Inc. (TSX: CRON) and Ginkgo Bioworks announced this morning that its partnership has...

Monday, August 23, 2021, 10:38:00 AM

Medipharm Labs and Cronos Group Sign Second Manufacturing Agreement

Medipharm Labs (TSX: LABS) and Cronos Group (TSX: CRON) (NASDAQ: CRON) have entered into their...

Thursday, September 19, 2019, 09:23:17 AM

Cronos Group: Raymond James Sees US$4.10/Share Valuation Just For Ginkgos Partnership

Raymond James recently upgraded Cronos Group (TSX: CRON) (NASDAQ: CRON) to an Outperform 2 rating...

Friday, July 3, 2020, 01:52:39 PM

Is 2020 The Year Cannabis Extractors Come Down With The Cronos Virus?

Our sharp-eyed editor Jay pointed out last week that cannabis cultivator Cronos Group Inc. (TSX:...

Sunday, March 15, 2020, 01:23:04 PM

Cronos Group Fails To File Timely Financials Due To Revenue Review

Cronos Group (TSX: CRON) (NASDAQ: CRON) filed its annual report this evening, also known as...

Monday, March 2, 2020, 08:04:03 PM